Independently ranked — no pay-to-rank · Built on the federal NPI registry · Who’s behind this

Featured research · Published in JAMA Network Open

Initial Treatment for Acute Low Back Pain and Risk of Opioid Use Disorder and Overdose

Authors: Lisa V Doan, Anton M Hung, Mark Olfson, Nicholas T Williams, Kara E Rudolph · JAMA Network Open, 2026 · Read the full published article

Featured on PainBeacon under the article's open license (CC BY 4.0). The abstract below is reproduced unchanged from the published article; the plain-English summary that follows is written by PainBeacon and reflects our editorial interpretation, not the authors' words. The authors did not review it and do not endorse PainBeacon.

Abstract

Importance: Guideline-discordant care for acute low back pain (aLBP) is common and has been associated with adverse outcomes.

Objectives: To estimate the incidence of new opioid use disorder (OUD) or overdose diagnosis among opioid-naive patients with Medicaid coverage initiating treatment for aLBP and to evaluate the association between initial treatment modalities and subsequent risk of OUD or overdose diagnosis.

Design, setting, and participants: This retrospective cohort study used data from January 1, 2016, to December 31, 2019, with 13 months of follow-up (1-month exposure assessment followed by 12 months of outcome follow-up) from the Transformed Medicaid Statistical Information System Analytic Files from 25 states that expanded Medicaid under the Patient Protection and Affordable Care Act by 2014. Participants included opioid-naive, adults aged less than 65 years who received pain treatment within 1 month of diagnosis of aLBP. Data were analyzed from March 1, 2025, to July 31, 2026.

Exposures: Initial pharmacologic and nonpharmacologic treatments for aLBP.

Main outcomes and measures: OUD or overdose diagnosis, defined using diagnostic codes for opioid abuse, opioid dependence, opioid-involved overdose, or a prescription for medication for treating OUD.

Results: In this cohort of 399 500 Medicaid patients who initiated treatment for newly diagnosed aLBP, the median age was 39 (IQR, 30-50) years, and 237 846 (59.5%) were female. The cumulative incidence of OUD or overdose diagnosis was 1.4% at 7 months and 2.3% at 13 months. Initiating vs not initiating higher-dose opioids (>50 mg of morphine equivalent) as part of the initial treatment was associated with the greatest risk, increasing risk of OUD or overdose by 146.6% (95% CI, 121.5%-171.7%). Initiating vs not initiating lower-dose opioids prescribed for more than 7 days or gabapentinoids each increased risk by 105.2% (95% CI, 89.0%-121.4%) and 101.6% (95% CI, 84.9%-118.2%), respectively. Nonpharmacologic, noninterventional therapies were associated with reductions in risk of OUD or overdose diagnosis. Initiating vs not initiating chiropractic care was associated with the largest relative risk reduction, decreasing risk by 32.8% (95% CI, 26.8%-38.9%), and initiating physical therapy was associated with 31.1% decreased risk (95% CI, 22.1%-40.1%).

Conclusions and relevance: In this cohort study, nonpharmacologic, noninterventional treatment was associated with reductions in risk of OUD or overdose diagnosis while initiating treatment with opioids or gabapentinoids was each associated with higher risks. These results support guideline recommendations favoring nonpharmacologic treatments as first-line therapy for aLBP.

Abstract reproduced unchanged from the published article under the Creative Commons Attribution 4.0 license (CC BY). Copyright 2026 Doan LV et al. JAMA Network Open. Read the full article at JAMA Network Open.


The PainBeacon plain-English summary

This summary is ours, not the authors'. For the study itself, see the abstract above and the published article.

What the study looked at. Researchers used Medicaid insurance records from 25 states, covering 2016 through 2019, to follow 399,500 adults under 65 who had just been diagnosed with acute low back pain. All of them were “opioid-naive” (not already taking opioids) and all received some treatment within a month of the diagnosis. The researchers recorded what each person’s first treatments were, including medications, physical therapy and chiropractic care, then counted how many went on to receive a new diagnosis of opioid use disorder or opioid overdose over the following 12 months. This is an analysis of insurance records, not a trial: nobody was assigned to a treatment.

What it found.

What it could not show. Cause and effect. The authors say so plainly: insurance records do not capture how severe a person’s pain was or how well they could function, so the groups may have differed in ways the analysis could not see. Diagnosis codes can misclassify people, over-the-counter and cash-paid medications were invisible to the study, and the results may not apply to people who are not on Medicaid.

Why it matters for patients. Guidelines from the American College of Physicians already recommend non-drug treatments first for a new episode of low back pain. This study adds a second reason beyond pain relief: in a very large group of patients, how treatment started was associated with what happened a year later. It does not mean an opioid prescription causes addiction, or that nobody should take one. The authors themselves write that medications can be considered after weighing benefits against longer-term risks, and that when opioids are prescribed, keeping the dose and duration low remains prudent.

If you are offered a prescription for new back pain, it is reasonable to ask what non-drug options are available and how long the prescription is meant to last. Our guide to pain management without opioids explains what those options are. Keep in mind that this study is about new, short-term back pain. It does not speak to people already being treated for chronic pain.

This summary is general education, not medical advice. Decisions about starting, changing, or stopping any medication belong with a licensed clinician who has examined you.

Funding and conflicts of interest

The study was funded by the National Institute on Drug Abuse, part of the U.S. National Institutes of Health (grant R01DA053243). The authors state that the funder had no role in designing or conducting the study, analyzing the data, or deciding to publish. One author, Dr. Doan, reported receiving personal fees from Health Monitor Network for editorial services outside this work. No other conflicts of interest were reported.

How to cite

Doan, L.V., Hung, A.M., Olfson, M., Williams, N.T., & Rudolph, K.E. (2026). Initial Treatment for Acute Low Back Pain and Risk of Opioid Use Disorder and Overdose. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.39420